Spyre Therapeutics, Inc.
DE ˙ DB ˙ US00773J2024
60,00 € ↑0,50 (0,84%)
2026-06-03
DEL PRIS
SecurityDE:3920 / Spyre Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership182,524 shares
Latest Disclosed Value $ 5,979,487
Barclays Plc reports 8.43% increase in ownership of 3920 / Spyre Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 182,524 shares of Spyre Therapeutics, Inc. (DE:3920) valued at $5,001,158 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 168,330 shares of Spyre Therapeutics, Inc.. This represents a change in shares of 8.43% during the quarter. The current value of the position is $10,951,440 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F SPYRE THERAPEUTICS COM 00773J202 182,524 14,194 8.43 5,979 111.95 0.0014
2026-03-31 2025-09-30 13F/A-3 SPYRE THERAPEUTICS COM 00773J202 168,330 -48,316 -22.30 2,821 -13.01 0.0006
2026-03-19 2025-09-30 13F/A-2 SPYRE THERAPEUTICS COM 00773J202 105,467 -111,179 3,102 0.0008
2025-11-12 2025-09-30 13F SPYRE THERAPEUTICS COM 00773J202 168,330 -48,316 2,821 0.0006
2026-02-27 2025-06-30 13F/A-2 SPYRE THERAPEUTICS COM 00773J202 216,646 2,040 0.95 3,243 -6.33 0.0007
2025-08-14 2025-06-30 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 216,646 2,040 3 0.0007
2025-08-13 2025-06-30 13F SPYRE THERAPEUTICS COM 00773J202 216,646 2,040 3 0.0002
2026-03-17 2025-03-31 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 214,606 91,535 74.38 3,463 20.84 0.0010
2025-05-15 2025-03-31 13F SPYRE THERAPEUTICS COM 00773J202 214,606 91,535 3 0.0010
2026-03-19 2024-12-31 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 123,071 17,604 16.69 2,865 -7.61 0.0008
2025-02-13 2024-12-31 13F SPYRE THERAPEUTICS COM 00773J202 123,071 17,604 3 0.0008
2026-03-31 2024-09-30 13F/A-2 SPYRE THERAPEUTICS COM 00773J202 105,467 41,424 64.68 3,102 106.05 0.0008
2024-11-19 2024-09-30 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 105,467 41,424 3 0.0008
2024-11-15 2024-09-30 13F SPYRE THERAPEUTICS COM 00773J202 105,467 41,424 3 0.0002
2026-03-23 2024-06-30 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 64,043 18,081 39.34 1,506 -13.65 0.0005
2024-08-14 2024-06-30 13F SPYRE THERAPEUTICS COM 00773J202 64,043 18,081 2 0.0005
2026-03-24 2024-03-31 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 45,962 464 1.02 1,743 78.04 0.0006
2024-05-15 2024-03-31 13F SPYRE THERAPEUTICS COM 00773J202 45,962 464 2 0.0006
2026-03-25 2023-12-31 13F/A-1 SPYRE THERAPEUTICS COM 00773J202 45,498 45,498 979 0.0004
2024-02-15 2023-12-31 13F SPYRE THERAPEUTICS COM 00773J202 45,498 45,498 1 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.